Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul P Cook

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Journal of General Virology|September 3, 2025
SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infectionBishwa R Pokharel, Niska Majumdar, Frank Williams, et al.
Virology|June 8, 2026
Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrainAbigail Dickerson, Andreea Cruceanu, Bishwa R Pokharel, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 22, 2022
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19Rosie S Jones, Patricia S Smith, Paul H Berg, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 19, 2022
Erratum: ErratumRosie S Jones, Patricia S Smith, Paul H Berg, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of General Virology|September 3, 2025
SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infectionBishwa R Pokharel, Niska Majumdar, Frank Williams, et al.
Virology|June 8, 2026
Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrainAbigail Dickerson, Andreea Cruceanu, Bishwa R Pokharel, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 22, 2022
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19Rosie S Jones, Patricia S Smith, Paul H Berg, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 19, 2022
Erratum: ErratumRosie S Jones, Patricia S Smith, Paul H Berg, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Pageof 4